Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Below is a chart showing LLY's trailing twelve month trading history, with the $830 strike highlighted in orange: Moderna Inc (Symbol: MRNA) options are showing a volume of 68,653 contracts thus ...

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...

Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

However, on the same day, Barclays maintained a Buy rating on Moderna (NASDAQ: MRNA). MRNA market cap is currently $19.33B and has a P/E ratio of -8.63. TipRanks tracks over 100,000 company insiders, ...